Review Article

Immunotherapy for Renal Cell Carcinoma

Momoe Itsumi and Katsunori Tatsugami

Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Correspondence should be addressed to Katsunori Tatsugami, ktatsu@uro.med.kyushu-u.ac.jp

Received 2 July 2010; Accepted 29 November 2010

Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical improvement. Recently, the importance of immune regulation by antigen-presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed. The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.

1. Introduction

Renal cell carcinoma (RCC), a glandular carcinoma, accounts for approximately 85%–95% of adult malignant kidney cancer cases [1]. Patients with advanced or metastatic disease have a poor prognosis, with a 5-year survival rate of less than 15%. Surgical treatment is effective, even in patients with advanced or metastatic RCC, because of its high resistance to chemotherapy and radiation therapy. Immunotherapy using interferon (IFN)-α and/or interleukin (IL)-2 has shown promising anti-tumor activity in RCC [2–4]. However, these cytokines have a positive effect in only 10%–20% of cases [5]. Like melanoma, RCC is classed as an immunogenic tumor based on its response rate to immunotherapy, the incidence of spontaneous regression, and the high level of tumor T cell infiltration. Despite its immunogenicity, only a few CD8+ cytotoxic-T-lymphocytes (CTLs), which can efficiently eliminate RCC cells, have been isolated [6]. This is in line with the small number of RCC-associated antigens that have so far been identified, thereby limiting the trials of candidate vaccines in these patients [7, 8].

Recently, tumor immunotherapy using DC has been shown to have therapeutic potential for malignant tumors. Moreover, nonmyeloablative stem cell transplantation (NST), which was developed for the treatment of leukemia, is effective against RCC [9, 10] and other solid tumors [11]. In this review, we discuss the current status of cell-mediated tumor-specific and nonspecific immunotherapy for RCC.

2. Tumor-Specific and Non-Specific Immunotherapy

In vivo studies show that cellular immunity mediated by T cells, natural killer (NK) cells or NK T cells plays a central role in the eradication of tumors. Since 1980, many attempts have been made to administer anti-tumor cells to cancer patients. In the late 1980s, human tumor antigens were identified and tumor-specific cellular immunity mediated via these tumor antigens received a lot of attention. Also, the administration of cytokines that activate cellular anti-tumor responses, including those mediated by T cells and NK cells, has been the subject of much research. It is thought that IFN-α induces Th1 cytokine production, thus promoting anti-tumor activity by cells that elicit cytotoxicity by acting directly on the tumor [12].
Table 1: Immunotherapy using inactivated tumor cells and a gene modified tumor vaccine (GMTV).

| Authors   | Vaccine                  | Adjuvant         | Patients | Duration of PFS/RFS | Results                  |
|-----------|--------------------------|------------------|----------|---------------------|-------------------------|
| Galligioni| Auto irrad tumor         | BCG              | 120      | 13 mo               | 5-year DFS 63%          |
|           |                          | (control 72%)    |          |                     | P = .21                  |
| Schwab    | Auto irrad tumor         | BCG, IFN-α, IFN-γ| 14       | —                   | 3 MR, 5 SD, 1 PD        |
| Dillman   | Auto irrad tumor         | BCG, IFN-α, IFN-β| 25       | 2.4 mo              | median survival 33.4 mo,|
|           |                          | GM-CSF, Cy       |          |                     | 5-year survival 43%     |
| Jocham    | Auto lysate              | None             | 379      | 47.8 mo             | 5-year PFS 77.4%        |
|           |                          |                  |          |                     | (control 67.8%) P = .02  |
| Dudek     | Auto LMI                 | None, Cy, Cy+IL-2| 31       | 2.8 mo              | None: 5 SD, Cy: 4 SD,   |
|           |                          |                  |          |                     | Cy+ IL-2: 1PR 3 SD      |
| May       | Auto lysate              | None             | 495      | —                   | 5 year, 10 year OS: 80.6, 68.9% |
|           |                          |                  |          |                     | (control 79.2, 62.1%) P = .066 |
| Simons    | Auto irrad tumor + GM-CSF| None            | 16       | —                   | 1 PR                    |
| Wittig    | Auto irrad tumor + GM-CSF, IL-7 | Oligonucleotides | 10       | —                   | 1 CR, 1 PR, 1 MR, 2 SD, 5 PD |
| Antonia   | Auto irrad tumor + B7.1 gene | IL-2     | 15       | —                   | 2 PR, 2 SD             |
| Tani      | Auto irrad tumor + GM-CSF | None           | 6        | —                   | 1 SD, 1 MR             |
| Pizza     | Auto irrad tumor + IL-2   | None            | 30       | 170.5 dy            | 1 CR, 4 PR, 9 SD       |
| Moiseyenko| Auto irrad tumor + tag7/PGPR-S gene | None    | 4        | 3 mo                | 1 SD, 1 MR             |
| Fishman   | Auto irrad tumor + B7.1 gene | IL-2    | 39       | —                   | 1 CR, 2 PR, 24 SD      |
| Buchner   | Auto irrad tumor + B7.1, IL-2 gene | None  | 12       | 5.3 mo              | PFS 5.3 mo, OS 15.6 mo |

LMI: large multivalent immunogen, Cy: cyclophosphamide, DFS: disease-free survival, Os: overall survival, PR: partial response, MR: mixed response, SD: stable disease, PD: progressive disease, PFS: progression-free survival, RFS: recurrence-free survival.

IL-2 is a growth/differentiation factor for NK cells and T cells, which induces and maintains the cytotoxicity, both these cell types [13]. Because cytokine treatment induces nonspecific anti-tumor activity, it is known as nonspecific immunotherapy.

In 1984, Mule et al. reported lymphokine-activated killer (LAK) cell treatment of tumors using inducible cultured cells [14]. Culturing immune cells isolated from a cancer patient’s peripheral blood, or excised tumor tissue, with IL-2 causes them to differentiate into LAK cells. Since the second half of the 1980s, treatment using LAK cells has been attempted in several facilities [15, 16]. However, because the treatment method causes severe side effects, it was never established as an effective treatment method. LAK cells have no tumor specificity because they are induced in culture in response to IL-2 alone and not by tumor antigens. Thus, it was thought that the adoptive transfer of LAK cells might result in damage to normal host cells in vivo.

Since Van Der Bruggen et al. identified tumor antigens that were specifically recognized by T cells in a melanoma-bearing patient [17], research became more focused on tumor-specific immunotherapy. Though LAK cells, CTLs, macrophages, NK cells and NKT cells are all involved in host immune response against tumors, CTLs are now thought to be one of the most important factors responsible for anti-tumor immunity.

3. Immunotherapy Using Inactivated Tumor Cells and Gene Modified Tumor Vaccines (GMTV)

Immunotherapy using inactivated tumor cells or tumor lysates is based on the idea that tumor cells express antigens that induce anti-tumor immune responses [18-22] (Table 1). Because immunotherapy using tumor cells is relatively straightforward, Jocham et al. undertook a large-scale randomized controlled trial and reported that the “non-replaced phase” after surgery for kidney cancer was extended by an autologous tumor vaccine [20]. The percentage of vaccinated patients showing no disease progression 5 years after treatment was 77.4% compared with 67.8% of the controls.

Both cytokines and antigen-presenting cells are important for the induction of effective immune responses [23]. Thus, GMTV was used to introduce virus-expressing
Clinical and Developmental Immunology

**Figure 1:** CTL induction by Apcs. Antigens are taken up and degraded into peptide fragments by antigen presenting cells (APC), such as immature DC. At some point on their path to the cell surface, newly synthesized MHC class II or I molecules bind the peptide antigen fragments and transport the peptides to the cell surface. CD8+ T cells recognizing the antigen expressed by weakly costimulatory cells become activated only in the presence of CD4+ T cells bound to the same APC. This happens via CD4+ T cells recognizing antigens presented by APCs and being triggered to induce increased levels of costimulatory activity by the antigen-presenting cell. The CD4+ T cells also produce increased amounts of IL-2, which drives CD8+ T cell proliferation. CD8+ T cells then become cytotoxic T lymphocytes (CTL).

Cytokines, or costimulatory molecules, into tumor cells (Table 1) [18–22, 24–33]. GMTV-immunotherapy introducing cytokine transgene, such as GM-CSF or IL-2, or costimulatory molecule transgene such as B7-1 into autologous irradiated tumors, has been carried out. However, these studies were disappointing in terms of a significant clinical response, such as tumor regression. Though the use of multiple tumor antigens should induce a greater immune response, one cannot rule out the possibility of unintentionally inhibiting anti-tumor immunity or of eliciting non-specific immune responses.

**4. Peptide-Based Immunotherapy**

Since the development of the SEREX method, which enables the identification of tumor antigens from cDNA libraries, many peptide-based vaccination studies have been undertaken. Because the effective induction of anti-tumor immunity using single peptides is difficult, MHC class II peptides have been used along with adjuvants (Table 2) [34–40]. HSPPC-96 (vitespen) is a heat shock protein. It is a peptide complex, in which the heat shock protein plays the role of an adjuvant. However, a recent randomized phase III study suggested that this complex did not improve recurrence-free survival rates [41]. Further studies are required to see whether antigen-specific T cells homogeneously induced by a single tumor antigen can be effective against a diverse population of tumor cells.

**5. DC-Based Immunotherapy**

Antigens processed within the proteasome of tumor cells are presented on major histocompatibility antigen (MHC) class I molecules of tumor cell as tumor antigen peptides that CTLs recognize, thus triggering CTL-mediated cytotoxicity. However, CTLs are not activated by direct recognition of the antigens expressed by tumor cells; they need help from dendritic cells (DCs) and CD4+ helper T cells. To activate a CD8+ T cell to become a CTL, engagement of the T cell receptor with a peptide antigen presented by an MHC class I molecule is not enough. The T cell must also recognize a costimulatory molecule (e.g. CD80 or CD86) (Figure 1). Moreover, antigen presenting cells (APCs) are activated through their interaction with CD4+ T cells, and then they express various costimulatory molecules. DCs are the most well-known and efficient APCs and are present in various tissues, including lymphoid and nonlymphoid organs and the blood, where they take up both particulate and soluble antigens before migrating to the lymph nodes to induce immune responses. Subsequently, DCs present antigen to T cells in the lymph nodes and induce antigen-specific immune responses, including the induction of CTLs. DCs also present antigen to other cells, including NK cells.

Clinical trials of DC therapy are listed in Table 3 [23, 35, 36, 42–59]. Although immunotherapy using DCs and nonautologous tumor cells seems to induce host immune cells to recognize tumor cells, there is still the possibility of alloreactive immune responses induced by nonself-antigens.
Because nonautologous DCs (allo-DCs) may be attacked by the host immune system, immunotherapy using autologous-DCs (auto DCs) might be more effective in vitro. To date, all reports regarding DC treatment are of phase I/II trials incorporating different methodologies. Although delayed-type hypersensitivity reactions in response to tumor cell lysates or keyhole limpet hemocyanin (KLH) and the production of IFN-γ by antigen-specific lymphocytes were observed, the number of patients showing a positive clinical response was still low.

We also used IFN-α as an adjunctive agent for DC therapy. As previously noted, IFN-α induced an environment conducive to DC activation and enhanced migratory competence [60, 61]. We evaluated the efficacy of DC-therapy in combination with IFN-α in patients with advanced RCC. After 4 months of vaccinations, five patients had stable disease and two had progressive disease. In six patients, the time-to-progression was prolonged compared with that seen after previous cytokine treatment. Because cytokine combination therapy induces the proliferation and maintenance of DC-activated T cells, combination therapy using IL-2 is reasonable. However, Oosterwijk et al. reported that combination therapy with IL-2 plus DCs was no more effective than DCs alone [44]. Recently, it was reported that IL-2 participates in the maintenance of regulatory T cells (Tregs), which suppress immune responses [62]. Further study of the role of IL-2 in immunotherapy is required.

### 6. Nonmyeloablative Stem Cell Transplantation (NST)

Though NST was developed for the treatment of leukemia, it began to gain attention as a treatment for solid tumors. In 2000, Childs et al. performed NST on 19 renal carcinoma patients and reported a success rate 53%; three patients were in complete remission and seven patients were in partial remission. Previous reports have highlighted the important role played by cellular anti-tumor immunity, including that mediated by donor T cells in graft versus host disease (GVHD) and the graft versus tumor effect (GVT); the appearance of GVHD induced by transplantation of donor T cells is inversely correlated with the rate of tumor recurrence. Recurrence is especially high in T cell-depleted stem cell transplants, and the administration of donor lymphocytes effectively reduces the incidence of recurrence [63, 64]. Donor T cells induce GVHD/GVT against recipient antigens, including MHC molecules, minor histocompatibility antigens and tumor cell-specific antigens. An effective GVT response can be induced if the antigen distribution between normal cells and tumor cells can be identified, and if donor T cell responses against normal cells can be controlled. Thus, in NST, the mechanism by which tumor specific immunity is induced is very important, and a recent study attempted to address the question of how this response was activated [65].

When the patient receives immunosuppressive treatment for GVHD, it might also cause suppression of the associated anti-tumor effects. In these patients, the differentiation of mononuclear cells into DCs is inhibited in vitro [66]. Therefore, when treating a patient with NST, one should bear in mind possible aggravation of the neoplasm by immunosuppressive therapy directed against GVHD.

### 7. Regulatory CD4+ T Cells and the Tumor

Recent research shows that CD4+ T cells constitutively expressing the IL-2 receptor α-chain (CD25) act in a regulatory capacity by suppressing the activation and function of other T cells [67]. Their physiological role is to protect the host against the development of autoimmunity by regulating immune responses against antigens expressed by normal tissues [68, 69]. Since tumor antigens are largely self-antigens, these so-called Treg cells may also prevent the tumor-bearing host from mounting an effective antitumor immune response. Previous studies have shown that elevated numbers of CD4+CD25+ Tregs can be found in patients with advanced cancer [70] and that high Treg frequencies are associated with reduced survival [71]. In our experiments into cytokine therapy for RCC patients, the number of CD4+ and FoxP3+Treg cells was significantly decreased after IFN-α treatment, and Treg cell levels before treatment correlated with the clinical response [72]. The important role of CD4+CD25+ Tregs in controlling tumor growth was further highlighted by the demonstration that depletion of Tregs using anti-CD25 antibodies evokes effective antitumor immunity in mice [73, 74]. Dannull et al. used a recombinant IL-2-diphtheria toxin conjugate (DAB389IL-2; also

### Table 2: Peptide-based immunotherapy.

| Authors | Stage  | Vaccine                        | Adjuvant                      | Patients | Duration of PFS/RFS | Results                        |
|---------|--------|--------------------------------|--------------------------------|----------|--------------------|--------------------------------|
| Uemura | mRCC   | CA9-derived peptide            | Incomplete Freund’s adjuvant  | 23       | 12.2 mo            | 3 PR, 6SD                      |
| Iiyama | mRCC   | WT 1-peptide                   | Incomplete Freund’s adjuvant  | 3        | —                  | 2 SD                           |
| Suekane | mRCC   | 4 different peptides           | None, IFN-α, IL-2             | 10       | 23 wk              | 6 SD                           |
| Wood   | cT1b-T4N0M0 or T4ant N1-2 M0  | HSPPC-96 (vitespen)           | None                           | 728      | 1.9 yr             | No difference in recurrence-free survival |
| Jonasch| mRCC   | HSPPC-96 (vitespen)            | None                           | 60       | 65 dy              | 2 CR, 2 PR, 7 SD               |

mRCC: metastatic RCC, PADRE: pan-MHC class II binding peptide, Auto mDC: autologous mature DC, CR: complete response, PR: partial response, SD: stable disease, PFS: progression-free survival, RFS: recurrence-free survival.
Table 3: DC-based immunotherapy.

| Authors              | Antigen                  | DC                          | Adjuvant   | Patients | Duration of PFS/RFS | Results                  |
|----------------------|--------------------------|-----------------------------|------------|----------|---------------------|--------------------------|
| Oosterwijk-Wakka     | Auto lysate              | Auto imDC                   | KLH/IL-2   | 12       | —                   | 8 SD, 4 PD               |
| Marten               | Auto lysate              | Auto mDC                    | KLH        | 15       | —                   | 1 PR, 7 SD, 7 PD         |
| Holtl                | Auto & Allo lysate       | Auto mDC                    | KLH        | 27       | 20.4 mo             | 2 CR, 1 PR, 7 SD, 17 PD  |
| Azuma                | Auto lysate              | Auto imDC                   | KLH        | 3        | —                   | 1 NC, 2 PD               |
| Marten               | DC/auto tumor fusion     | Allo mDC                    | —          | 12       | —                   | 4 SD, 8 PD               |
| Su                   | tumor RNA                | Auto imDC                   | —          | 10       | —                   | not evaluated            |
| Gitliz               | Auto lysate              | Auto imDC                   | —          | 12       | —                   | 1 PR, 3 SD, 8 PD         |
| Barbuto              | DC/auto tumor fusion     | Allo mDC                    | —          | 19       | 5.7 mo              | 30 R, 14 SD, 2 PD        |
| Avigan               | DC/auto tumor fusion     | Auto imDC                   | KLH        | 13       | 4.2 mo              | 5 SD, 8 PD               |
| Pandha               | Allo lysate              | Auto imDC                   | KLH        | 5        | —                   | 2 SD                     |
| Arroyo               | Auto lysate              | Auto mDC                    | KLH        | 5        | 9.6 mo (5–16)       | 3 SD                     |
| Holtl                | Auto & Allo TuLy         | Allo mDC                    | KLH/Cy     | 20       | 22.3 mo             | 2 MR, 3 SD, 15 PD        |
| Wierecky             | MUC-1 peptide            | Auto mDC                    | PADRE      | 20       | 10.8 mo (4–24)      | 1 CR, 2 MR, 2 PR, 5 SD, 10 PD |
| Bleumer              | CA9 peptide              | Auto mDC                    | KLH CA9 class II peptide | 6  | —                   | 6 PD                     |
| Wei                  | DC/auto tumor fusion     | Auto mDC                    | IL-2       | 10       | 7 mo (5–12)         | 1 PR, 3 SD, 6 PD         |
| Matsumoto            | Auto lysate              | Auto mDC                    | KLH        | 3        | —                   | 1 SD, 2 PD               |
| Kim                  | Auto lysate              | Auto mDC                    | KLH        | 9        | 5.2 mo              | 1 PR, 3 SD, 3 PD         |
| Berntesen            | Lysate or surviving and telomerase peptides | Auto mDC | IL-2 | 27 | 2.7 mo | 13 SD, 14 PD |
| Tatsugami            | Auto TuLy                | Auto mDC                    | IFN-α      | 7        | 7.8 mo              | 5 SD, 2 PD               |
| Zbou                 | DC/auto tumor fusion     | Allo mDC                    | —          | 10       | —                   | 1 PR, 6 SD, 3 PD         |

Cy: cyclophosphamide, PADRE: pan-MHC class II binding peptide, Auto mDC: autologous mature DC, Allo imDC: allogeneic immature DC CR: complete response, PR: partial response, MR: mixed response, SD: stable disease, OR: objective response, PD: progressive disease, PFS: progression-free survival, RFS: recurrence-free survival.

Known as denileukin diftitox and ONTAK) to eliminate CD25-expressing Tregs in metastatic RCC patients, and reported that depletion of Tregs in RCC patients followed by vaccination with tumor RNA-transfected DCs led to improved stimulation of tumor-specific T cells compared with vaccination alone [75]. It will be critical to collect accurate information regarding Tregs to address the clinical efficacy of such strategies in cancer patients.

8. Conclusions

The use of immunotherapy using cultured cells, such as DCs, to treat large numbers of patients, and the conduction of large-scale studies are difficult because of the problems associated with the need for adequate culture facilities and appropriate culture techniques. Because of the complexity of the immune responses involved, it is difficult to evaluate the efficacy of immunotherapy compared with other treatments. However, as it is clear that the immune system plays a significant role in the control of tumors, continued analysis of the mechanisms involved in tumor immunity and the development of new immunotherapies are vital.

References

[1] P. F. A. Mulders, A. H. Brouwers, C. A. Hulsbergen-van Der Kaa, E. N. J. TH. Van Lin, S. Osanto, and P. H. M. De Mulder, “Guideline ‘Renal cell carcinoma,’” Nederlands Tijdschrift voor Geneeskunde, vol. 152, no. 7, pp. 376–380, 2008.
[2] D. T. Alexandrescu and C. A. Dasanu, “Kidney cancer therapy: new perspectives and avenues,” Expert Opinion on Pharmacotherapy, vol. 7, no. 18, pp. 2481–2493, 2006.
[3] J. C. Yang and R. Childs, “Immunotherapy for renal cell cancer,” Journal of Clinical Oncology, vol. 24, no. 35, pp. 5576–5583, 2006.
[4] R. J. Motzer and R. M. Bukowski, "Targeted therapy for metastatic renal cell carcinoma," *Journal of Clinical Oncology*, vol. 24, no. 35, pp. 5601–5608, 2006.

[5] B. C. Leibovich, K. R. Han, M. H. T. Bui et al., "Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials," *Cancer*, vol. 98, no. 12, pp. 2566–2575, 2003.

[6] J. H. Finke, P. Rayman, M. Edinger et al., "Characterization of a human renal cell carcinoma specific cytotoxic CD8 T cell line," *Journal of Immunotherapy*, vol. 11, no. 1, pp. 1–11, 1992.

[7] N. Brouwenstijn, B. Gaugler, K. M. Kruse et al., "Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes," *International Journal of Cancer*, vol. 68, no. 2, pp. 177–182, 1996.

[8] C. Gaudin, F. Kremer, E. Angevini, V. Scott, and F. Triebel, "A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma," *Journal of Immunology*, vol. 162, no. 3, pp. 1730–1738, 1999.

[9] R. Childs, A. Chernoff, N. Contentin et al., "Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation," *New England Journal of Medicine*, vol. 343, no. 11, pp. 750–758, 2000.

[10] B. I. Rini, T. Zimmerman, W. M. Stadler, T. F. Gajewski, and N. J. Vogelzang, "Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results," *Journal of Clinical Oncology*, vol. 20, no. 8, pp. 2017–2024, 2002.

[11] S. Slavin, A. Nagler, E. Naparstek et al., "Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytokreduction for the treatment of malignant and nonmalignant hematologic diseases," *Blood*, vol. 91, no. 3, pp. 756–763, 1998.

[12] F. Belardelli, M. Ferrantini, E. Proietti, and J. M. Kirkwood, "Interferon-alpha in tumor immunity and immunotherapy," *Cytokine and Growth Factor Reviews*, vol. 13, no. 2, pp. 119–134, 2002.

[13] K. A. Margolin, "Interleukin-2 in the treatment of renal cancer," *Seminars in Oncology*, vol. 27, no. 2, pp. 194–203, 2000.

[14] J. J. Mule, S. Shu, S. L. Schwarz, and S. A. Rosenberg, "Adaptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2," *Science*, vol. 225, no. 4669, pp. 1487–1489, 1984.

[15] S. Negrier, T. Philip, G. Stoter et al., "Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study," *European Journal of Cancer and Clinical Oncology*, vol. 25, supplement 3, pp. S21–S28, 1989.

[16] J. P. Kuebler, R. P. Whitehead, D. L. Ward, G. P. Hemstreet, E. C. Bradley, and J. B. DeKernion, "Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells," *Journal of Urology*, vol. 150, no. 3, pp. 814–820, 1993.

[17] P. Van Der Bruggen, C. Traversari, P. Chomez et al., "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma," *Science*, vol. 254, no. 5038, pp. 1643–1647, 1991.

[18] E. Galligioni, M. Quaia, A. Merlo et al., "Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guérin: five-year results of a prospective randomized study," *Cancer*, vol. 77, no. 12, pp. 2560–2566, 1996.

[19] T. Schwab, J. A. Heaney, A. R. Schned et al., "A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon y and human recombinant interferon α2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters," *Journal of Urology*, vol. 163, no. 4, pp. 1322–1327, 2000.

[20] D. Jocham, A. Richter, L. Hoffmann et al., "Adjuvant autologous tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial," *Lancet*, vol. 363, no. 9409, pp. 594–599, 2004.

[21] A. Z. Dudek, M. F. Mescher, I. Okazaki et al., "Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma," *American Journal of Clinical Oncology: Cancer Clinical Trials*, vol. 31, no. 2, pp. 173–181, 2008.

[22] R. Dillman, N. Barth, L. VanderMolen et al., "Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma," *Cancer Biotherapy and Radiopharmaceuticals*, vol. 19, no. 5, pp. 570–580, 2004.

[23] K. Tatsugami, M. Eto, M. Harano et al., "Dendritic cell therapy in combination with interferon-α for the treatment of metastatic renal cell carcinoma," *International Journal of Urology*, vol. 15, no. 8, pp. 694–698, 2008.

[24] S. J. Antonia, J. Seigne, J. Diaz et al., "Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma," *Journal of Urology*, vol. 167, no. 3, pp. 995–2000, 2002.

[25] M. May, F. Kendel, B. Hoschke et al., "Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma: overall survival analysis with a follow-up period in excess of more than 10 yearsAdjuvante autologe Tumorvakzine beim Nierenzellkarzinom: gesamtüberlebensanalyse mit einem Nachbeobachtungszeitraum von mehr als 10 Jahren," *Urologe A*, vol. 46, no. 9, pp. 1075–1083, 2009.

[26] A. Buchner, H. Fohla, G. Willimsky et al., "Phase I trial of allogene gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma," *Human Gene Therapy*, vol. 21, no. 3, pp. 285–297, 2010.

[27] R. O. Dillman, N. M. Barth, L. A. VanderMolen et al., "Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma," *Cancer Biotherapy and Radiopharmaceuticals*, vol. 16, no. 1, pp. 47–54, 2001.

[28] J. W. Simons and B. Mikhak, "Ex vivo gene therapy using tumor cell line-derived vaccine for patient-specific treatment of metastatic carcinoma by expression-modulated and anti-tumor cell line-derived vaccine for patient-specific treatment of metastatic carcinoma by expression-modulated and human recombinant interferon γ phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon α2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters," *Journal of Urology*, vol. 163, no. 4, pp. 1322–1327, 2000.

[29] D. Jocham, A. Richter, L. Hoffmann et al., "Adjuvant autologous tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial," *Lancet*, vol. 363, no. 9409, pp. 594–599, 2004.

[30] A. Z. Dudek, M. F. Mescher, I. Okazaki et al., "Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma," *American Journal of Clinical Oncology: Cancer Clinical Trials*, vol. 31, no. 2, pp. 173–181, 2008.
[31] K. Tani, M. Azuma, Y. Nakazaki et al., “Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings,” Molecular Therapy, vol. 10, no. 4, pp. 799–816, 2004.

[32] G. Pizza, C. De Vinci, G. Lo Conte et al., “Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II,” Folia Biologica, vol. 50, no. 6, pp. 175–183, 2004.

[33] V. M. Moiseyenko, A. O. Danilov, I. A. Baldueva et al., “Phase II/II trial of gene therapy with autologous tumor cells modified with tag7/PGPR-S gene in patients with disseminated solid tumors,” Annals of Oncology, vol. 16, no. 1, pp. 162–168, 2005.

[34] H. Uemura, K. Fujimoto, M. Tanaka et al., “A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma,” Clinical Cancer Research, vol. 12, no. 6, pp. 1768–1775, 2006.

[35] J. Wierecky, M. Mueller, and P. Brossart, “Dendritic cell-based cancer immunotherapy targeting MUC-1,” Cancer Immunology, Immunotherapy, vol. 55, no. 1, pp. 63–67, 2006.

[36] I. Bleumer, D. M. Tiemessen, J. C. Oosterwijk-Wakka et al., “Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells,” Journal of Immunotherapy, vol. 30, no. 1, pp. 116–122, 2007.

[37] T. Iiyama, K. Udaka, S. Takeda et al., “WT1 (Wilms’ tumor 1) peptide immunotherapy for renal cell carcinoma,” Microbiology and Immunology, vol. 51, no. 5, pp. 519–530, 2007.

[38] S. Suekane, M. Nishitani, M. Noguchi et al., “Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients,” Cancer Science, vol. 98, no. 12, pp. 1965–1968, 2007.

[39] C. Wood, P. Srivastava, R. Bukowski et al., “An adjuvant autologous therapeutic vaccine (HSPPC-96; vitesspen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial,” The Lancet, vol. 372, no. 9633, pp. 145–154, 2008.

[40] E. Jonasch, C. Wood, P. Tamboli et al., “Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitesspen vaccine: clinical findings,” British Journal of Cancer, vol. 98, no. 8, pp. 1336–1341, 2008.

[41] H. Van Poppel, S. Joniau, and S. W. Van Gool, “Vaccine therapy in patients with renal cell carcinoma,” European Urology, vol. 55, no. 6, pp. 1333–1344, 2009.

[42] Y. C. Wei, R. P. Sticca, J. Li et al., “Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: a pilot study,” Oncology Reports, vol. 18, no. 3, pp. 665–671, 2007.

[43] J. H. Kim, Y. Lee, Y. S. Bae et al., “Phase II/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma,” Clinical Immunology, vol. 125, no. 3, pp. 257–267, 2007.

[44] J. C. Oosterwijk-Wakka, D. M. Tiemessen, I. Bleumer et al., “Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study,” Journal of Immunotherapy, vol. 25, no. 6, pp. 500–508, 2002.

[45] A. Märtens, D. Flieger, S. Renoth et al., “Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial,” Cancer Immunology, Immunotherapy, vol. 51, no. 11-12, pp. 637–644, 2002.

[46] L. Hölt, C. Zelle-Rieser, H. Gander et al., “Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells,” Clinical Cancer Research, vol. 8, no. 11, pp. 3369–3376, 2002.

[47] T. Azuma, S. Horie, K. Tomita et al., “Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: university of Tokyo experience,” International Journal of Urology, vol. 9, no. 6, pp. 340–346, 2002.

[48] A. Märtens, S. Renoth, T. Heinicke et al., “Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/I trial in patients with metastatic renal cell carcinoma,” Human Gene Therapy, vol. 14, no. 5, pp. 483–494, 2003.

[49] Z. Su, J. Dannull, A. Heiser et al., “Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells,” Cancer Research, vol. 63, no. 9, pp. 2127–2133, 2003.

[50] B. J. Girit, Z. H. Belldegrun, A. Zisman et al., “A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma,” Journal of Immunotherapy, vol. 26, no. 5, pp. 412–419, 2003.

[51] J. A. M. Barbuto, L. F. C. Ensina, A. R. Neves et al., “Dendritic cell-tumor cell hybrid vaccination for metastatic cancer,” Cancer Immunology, Immunotherapy, vol. 53, no. 12, pp. 1111–1118, 2004.

[52] H. S. Pandha, R. J. John, J. Hutchinson et al., “Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study,” BJU International, vol. 94, no. 3, pp. 412–418, 2004.

[53] J. C. Arroyo, F. Gabilondo, L. Llorente, M. A. Meraz-Rios, and C. Sanchez-Torres, “Tumors induced in vitro by CD16 and CD16 monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines,” Journal of Clinical Immunology, vol. 24, no. 1, pp. 86–96, 2004.

[54] J. Wierecky, M. R. Muller, S. Wirths et al., “Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients,” Cancer Research, vol. 66, no. 11, pp. 5910–5918, 2006.

[55] A. Matsumoto, K. Haraguchi, T. Takahashi et al., “Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells,” International Journal of Urology, vol. 14, no. 4, pp. 277–283, 2007.

[56] A. Berntsen, R. Trepiakas, L. Wenandy et al., “Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial,” Journal of Immunotherapy, vol. 31, no. 8, pp. 771–780, 2008.

[57] J. Zhou, D. Weng, F. Zhou et al., “Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses,” Cancer Immunology, Immunotherapy, vol. 58, no. 10, pp. 1587–1597, 2009.

[58] L. Hölt, R. Ramoner, C. Zelle-Rieser et al., “Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide,” Cancer Immunology, Immunotherapy, vol. 54, no. 7, pp. 663–670, 2005.

[59] D. Avigan, B. Vasi, J. Gong et al., “Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses,” Clinical Cancer Research, vol. 10, no. 14, pp. 4699–4708, 2004.

[60] T. Luft, P. Luetscher, H. Hochrein et al., “IFN-α enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells,” International Immunology, vol. 14, no. 4, pp. 367–380, 2002.
E. Padovan, G. C. Spagnoli, M. Ferrantini, and M. Heberer, “IFN-α2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8 effector T cells,” Journal of Leukocyte Biology, vol. 71, no. 4, pp. 669–676, 2002.

H. Zhang, K. S. Chua, M. Guimond et al., “Lymphopenia and interleukin-2 therapy alter homeostasis of CD4 CD25 regulatory T cells,” Nature Medicine, vol. 11, no. 11, pp. 1238–1243, 2005.

M. M. Horowitz, R. P. Gale, P. M. Sondel et al., “Graft-versus-leukemia reactions after bone marrow transplantation,” Blood, vol. 75, no. 3, pp. 555–562, 1990.

H. J. Kolb, J. Mittermuller, C. Clemm et al., “Donor leukocyte transusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients,” Blood, vol. 76, no. 12, pp. 2462–2465, 1990.

M. Harano, M. Eto, T. Iwai et al., “Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice,” Cancer Research, vol. 65, no. 21, pp. 10032–10040, 2005.

K. Tatsugami, M. Eto, M. Harano et al., “Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma,” Lancet Oncology, vol. 5, no. 12, pp. 750–752, 2004.

E. M. Shevach, “Certified professionals: CD4CD25 suppressor T cells,” Journal of Experimental Medicine, vol. 193, no. 11, pp. F41–F45, 2001.

H. Ionuleit, E. Schmitt, G. Schuler, J. Knop, and A. H. Enk, “Induction of interleukin 10-producing, nonproliferating CD4 T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells,” Journal of Experimental Medicine, vol. 192, no. 9, pp. 1213–1222, 2000.

S. Read and F. Powrie, “CD4 regulatory T cells,” Current Opinion in Immunology, vol. 13, no. 6, pp. 644–649, 2001.

E. Y. Woo, H. Yeh, C. S. Chu et al., “Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation,” Journal of Immunology, vol. 168, no. 9, pp. 4272–4276, 2002.

T. J. Curiel, G. Coukos, L. Zou et al., “Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival,” Nature Medicine, vol. 10, no. 9, pp. 942–949, 2004.

K. Tatsugami, M. Eto, and S. Naito, “Influence of immunotherapy with interferon-α on regulatory T cells in renal cell carcinoma patients,” Journal of Interferon and Cytokine Research, vol. 30, no. 1, pp. 43–48, 2010.

J. Shimizu, S. Yamazaki, and S. Sakaguchi, “Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity,” Journal of Immunology, vol. 163, no. 10, pp. 5211–5218, 1999.

S. Onizuka, I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama, “Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody,” Cancer Research, vol. 59, no. 13, pp. 3128–3133, 1999.

J. Dannull, Z. Su, D. Rizzieri et al., “Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells,” Journal of Clinical Investigation, vol. 115, no. 12, pp. 3623–3633, 2005.